PRESS RELEASE published on 05/15/2023 at 09:00, 3 years 3 months ago Andera Partners co-leads a €40 million Series A of Dualyx, a Belgian biotech developing novel Treg therapies for autoimmune diseases
PRESS RELEASE published on 05/10/2023 at 09:00, 3 years 4 months ago Andera Partners appoints Stefan Keitel Senior Advisor DACH region further strengthening its presence in the German, Austrian and Swiss private equity markets
PRESS RELEASE published on 04/18/2023 at 09:15, 3 years 4 months ago Andera Partners co-leads a Series A extension round totalling € 47.75 million for radiopharmaceutical company Ariceum Therapeutics
PRESS RELEASE published on 04/13/2023 at 12:45, 3 years 4 months ago Andera Partners leads $48.5 Million Series A financing for medical device company BioVentrix®
PRESS RELEASE published on 03/15/2023 at 13:05, 3 years 5 months ago Andera Partners co-leads $25m extension round for FIRE1, an Irish medtech developing breakthrough technology for patients with heart failure
PRESS RELEASE published on 02/16/2023 at 09:00, 3 years 6 months ago Ahead of its business plan, Andera Partners approaches 4 billion euros in assets under management and announces a new 2028 target of 6 to 8 billion euros
PRESS RELEASE published on 02/14/2023 at 09:00, 3 years 6 months ago Andera Partners Portfolio Company Mineralys Therapeutics Successfully Completes Upsized $192 Million Nasdaq IPO
PRESS RELEASE published on 01/26/2023 at 13:10, 3 years 7 months ago Andera Partners Participates in the €45 Million Series B Financing of Grey Wolf Therapeutics, led by Pfizer Ventures, to Advance First-of-its-Kind Neoantigen Creation Approaches
PRESS RELEASE published on 01/10/2023 at 08:30, 3 years 8 months ago Andera Partners invests in SoniVie, a medtech company developing a promising device for the treatment of hypertension
PRESS RELEASE published on 01/09/2023 at 14:00, 3 years 8 months ago Andera Partners participates in the $138 Million Series C Financing of Amolyt Pharma led by Sofinnova Partners and co-led by Intermediate Capital Group
Published on 09/11/2026 at 17:00, 2 hours 5 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/11/2026 at 17:00, 2 hours 5 minutes ago Critical Elements sélectionné pour inclusion dans le prospectus du sommet Canadien de l'investissement, mettant le projet en valeur auprès d'investisseurs mondiaux de premier plan
Published on 09/11/2026 at 15:25, 3 hours 40 minutes ago Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 4 hours 5 minutes ago Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 4 hours 35 minutes ago AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 18:15, 50 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 18:00, 1 hour 5 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 18:00, 1 hour 5 minutes ago ROCTOOL: INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 09/11/2026 at 07:00, 12 hours 5 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 12 hours 5 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 12 hours 5 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 23 hours 35 minutes ago Availability of the 2026 Interim Financial Report
